New combo therapy takes on deadly thyroid cancer in early trial

NCT ID NCT03975231

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two targeted drugs (dabrafenib and trametinib) with a precise form of radiation therapy (IMRT) is safe and can shrink tumors in people with a rare and aggressive thyroid cancer that has a specific BRAF mutation. Only 6 participants will be enrolled to find the best dose and look for early signs of response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dabrafenib and Trametinib (targeted drugs) plus Intensity-Modulated Radiation Therapy (IMRT)
What this could lead to: If successful, this could point toward a new treatment option for people with this aggressive thyroid cancer that has a BRAF mutation.
What could go wrong: This is a very early phase 1 trial with only 6 participants, so it is primarily testing safety and dosing. It is too small to prove effectiveness, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF NP_004324.2:P.V600E are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF NP_004324.2:P.V600E BRAF V600K MUTATION PRESENT THYROID GLAND ANAPLASTIC CARCINOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Univ of Texas-M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.